Dennis Purcell

Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline.

Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA.

Cengent Therapeutics, Inc. used to research and develop pharmaceutical drugs. It was a structure-based drug discovery company with a primary focus on compounds targeting signal transduction for the treatment of obesity and diabetes. It used to discover orally active PTP-1B inhibitors for treatment of type II diabetes and obesity. It was headquartered in San Diego, CA.

Aisling Capital LLC (Aisling Capital) is an venture capital firm founded in 1999 by Dennis Joseph Purcell. The firm is headquartered in New York, New York.

Bridge Laboratories is a preclinical contract research organization (CRO) that provides US-level regulatory-compliant drug development services globally. Bridge is known for its extensive work in toxicology, including vaccines, and safety pharmacology. The company's AAALAC-accredited facility in China was among the first labs to perform GLP studies for clients worldwide. Bridge Laboratories gives drug development clients-biotech/pharmaceutical firms, government agencies and virtual companies with strong outsourcing needs-a CRO choice that can dramatically improve the speed and cost-effectiveness of their drug development research programs.

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Embera NeuroTherapeutics, Inc. develops treatments for smoking cessation, cocaine dependence and other addictions. The company was founded by Nicholas Edward Goeders and Marie A. Lindner in 2005 and is headquartered in Sudbury, MA.

Dynova Laboratories, Inc. operates as a consumer health products company with deep sales and marketing expertise. It focuses on acquiring and developing natural supplements/OTC products. The company identifies brands, companies, and technologies for licensing or acquisition; and provides clinical, marketing, packaging, and sales support for dietary or natural supplements category. Dynova Laboratories was founded in 2006 and is headquartered in Parsippany, NJ.